Literature DB >> 3501941

Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.

D D Richman1.   

Abstract

The antiviral activities of various dideoxynucleosides against LAV strains of human immunodeficiency viruses type 1 (HIV-1) and type 2 (HIV-2) were evaluated. Significantly more 3'-azido-3'-deoxythymidine was required to inhibit the replication of HIV-2 than HIV-1 in three human cell lines. HIV-2 also appeared more resistant than HIV-1 to other dideoxynucleosides. These results suggest that dideoxynucleosides may be less effective in vivo for HIV-2 infection and that a broader range of clinical isolates of human retroviruses should be examined for drug susceptibility in vitro.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3501941      PMCID： PMC175819          DOI： 10.1128/AAC.31.12.1879

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA.

Authors:  G E FOLEY; H LAZARUS; S FARBER; B G UZMAN; B A BOONE; R E MCCARTHY
Journal:  Cancer       Date:  1965-04       Impact factor: 6.860

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

4.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

5.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728
View more
  10 in total

Review 1.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

Authors:  R W Shafer; J A Eisen; T C Merigan; D A Katzenstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Human immunodeficiency virus type 2.

Authors:  G Hammond
Journal:  CMAJ       Date:  1989-01-15       Impact factor: 8.262

5.  Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3'-azido-3'-deoxythymidine triphosphate.

Authors:  L Vrang; B Oberg; J Löwer; R Kurth
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

6.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.

Authors:  B A Larder; B Chesebro; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 7.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

8.  Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Authors:  Robert A Smith; Geoffrey S Gottlieb; Donovan J Anderson; Crystal L Pyrak; Bradley D Preston
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

9.  Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine.

Authors:  V A Johnson; B D Walker; M A Barlow; T J Paradis; T C Chou; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 10.  An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Authors:  Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2015-11-02       Impact factor: 11.413
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.